Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AbobotulinumtoxinA Dose-Ranging for Glabellar Lines
NCT03736928Phase 2Completed
- Sponsor
- Galderma
- Start
- Nov 2018
- Primary completion
- Dec 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of botulinum toxin type A in glabellar lines (4 arms), sponsored by Galderma. Primary endpoint: Number of Composite Responders at Month 1. Started Nov 2018; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
glabellar lines
Beyond the preview
Go deeper on NCT03736928.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03736928.